COMMUNIQUÉS West-GlobeNewswire

Tabula Rasa HealthCare Announces Proposed $250 Million Offering of Convertible Notes
07/02/2019
MOORESTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) (“TRHC”) today announced its intention to offer, subject to market and other conditions, $250 million principal amount of [...]
Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2018 Financial Results on March 14, 2019
07/02/2019
NEWTOWN, Pa., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that fourth [...]
Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device
07/02/2019
Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain Aneurysms DUBLIN - February 7, 2019 - Medtronic plc (NYSE:MDT) announced [...]
BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day
07/02/2019
CAMBRIDGE, Mass., and BEIJING, China, Feb. 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018
07/02/2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV [...]
Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates
07/02/2019
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing [...]
Ogilvy Health's Mangold and McKenna to be inducted into the Medical Advertising Hall of Fame's Future Famers Program
07/02/2019
PARSIPPANY, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Ogilvy Health ( www.ogilvychww.com ), the health practice of Ogilvy, a WPP company (NASDAQ: WWPGY) ( www.wpp.com ), today announced Brittany Mangold, Account [...]
T2 Biosystems Reports Granting of Inducement Awards
07/02/2019
LEXINGTON, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, [...]
Merus to Participate in Guggenheim Healthcare Talks Idea Forum
07/02/2019
UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today [...]
Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)¹
07/02/2019
First ever approved Peptide Receptor Radionuclide Therapy in Canada Neuroendocrine tumors are rare malignancies that affect approximately 12,000-15,000 Canadians 2 SAINT-GENIS-POUILLY, France, Feb. 07, 2019 (GLOBE [...]
AMAG Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
07/02/2019
Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- AMAG [...]
Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property
07/02/2019
Mayfield, a women’s health focused drug development company, intends to seek FDA approval for MAY-44 Dyspareunia treatment drug candidate via the 505(b)(2) approval pathway SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- [...]
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
07/02/2019
- Company expediting planned dose escalation activities - - Low levels of SGT-001 microdystrophin protein detected at the starting dose - - Conference call to be held at 8:30 a.m. ET today - CAMBRIDGE, Mass., Feb. 07, [...]
LHC Group Announces Fourth Quarter 2018 Earnings Release and Conference Call Dates
07/02/2019
LAFAYETTE, La., Feb. 07, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc . (NASDAQ: LHCG) today announced details for the release of its results for the fourth quarter and year ended December 31, 2018. LHC Group plans to issue [...]
C-RAD and XECAN announce strategic development and sales cooperation
07/02/2019
C-RAD and the US based company XECAN signed a partnership agreement to develop new products to advance patient positioning and resource management within radiation therapy. The development work will start immediately [...]
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2019 Financial Results on February 12, 2019
07/02/2019
Financials for Third Quarter Fiscal Year 2019 Ended December 31, 2018 will be released February 11, 2019 Northvale, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB: [...]
RavenQuest Issues Statement in Response to Health Canada Sales License Suspension at Bonify
07/02/2019
VANCOUVER, British Columbia, Feb. 07, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) CEO, George Robinson, also acting President & CEO at [...]
CellaVision AB Year-end bulletin, Jan-Dec 2018
07/02/2019
CellaVision's best quarter ever with strong growth October 1 - December 31, 2018 · Net sales increased by 46% to SEK 111,0 million (76.1). · Organic growth increased to 44% (6) · Operating profit increased to SEK 35.8 [...]
Sanofi delivers 2018 business EPS growth of 5.1% at CER
07/02/2019
Paris, February 7, 2019 Sanofi delivers 2018 business EPS growth of 5.1% at CER Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales reported €8,997m +3.5% +3.9% €34,463m -1.7% +2.5% IFRS net income [...]

Pages